Jeyakumar SM, Vajreswari A. Stearoyl-CoA desaturase 1: A potential target for non-alcoholic fatty liver disease?-perspective on emerging experimental evidence. World J Hepatol 2022; 14(1): 168-179 [PMID: 35126846 DOI: 10.4254/wjh.v14.i1.168]
Corresponding Author of This Article
Shanmugam Murugaiha Jeyakumar, PhD, Senior Scientist, Department of Clinical Pharmacology, National Institute for Research in Tuberculosis, No. 1 Mayor Sathiyamoorthy Road, Chetpet, Chennai 600031, Tamil Nadu, India. smjkumar@gmail.com
Research Domain of This Article
Biochemistry & Molecular Biology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Shanmugam Murugaiha Jeyakumar, Ayyalasomayajula Vajreswari, Division of Lipid Biochemistry, National Institute of Nutrition, Hyderabad 500007, Telangana, India
Shanmugam Murugaiha Jeyakumar, Department of Clinical Pharmacology, National Institute for Research in Tuberculosis, Chennai 600031, Tamil Nadu, India
Author contributions: Jeyakumar SM contributed to conception, summary art drawing, and drafting, reviewing, and finalization of the manuscript; Vajreswari A contributed to critical reviewing of the manuscript.
Supported byIndian Council of Medical Research (ICMR), No. 5/4/3-10/TF/2011/NCD-II; Department of Biotechnology (DBT), No. BT/PR6145/FNS/20/566/2012; and ICMR-NIN-Intramural Grant.
Conflict-of-interest statement: The authors declare no conflict of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Shanmugam Murugaiha Jeyakumar, PhD, Senior Scientist, Department of Clinical Pharmacology, National Institute for Research in Tuberculosis, No. 1 Mayor Sathiyamoorthy Road, Chetpet, Chennai 600031, Tamil Nadu, India. smjkumar@gmail.com
Received: May 3, 2021 Peer-review started: May 3, 2021 First decision: June 15, 2021 Revised: June 18, 2021 Accepted: December 10, 2021 Article in press: December 10, 2021 Published online: January 27, 2022
Core Tip
Core Tip: Stearoyl-CoA desaturase 1 (SCD1) is the rate-limiting enzyme of biosynthesis of monounsaturated fatty acids that serve as substrates for de novo lipogenesis, thereby increasing the production and accumulation of triglycerides in the liver. The liver-specific inhibition of SCD1 has been shown to attenuate the development of hepatic steatosis and thus non-alcoholic fatty liver disease (NAFLD), as evidenced by experimental studies. The current evidence supports the view that SCD1 is a potential target and the inhibition of this enzyme would certainly help in the control and/or management of NAFLD in humans. However, certain aspects of SCD1 such as its role and regulation need to be addressed in humans to explore its potential translational applicability.
